Infliximab: Nursing Drug Guide, Infusion Reactions & TB Screening
Infliximab is a weight-based IV TNF blocker with a boxed warning for serious infections—including tuberculosis reactivation—and malignancy. Nurses must confirm infection and latent TB clearance before each infusion, monitor continuously for dyspnea, hypotension, and urticaria during the ≥2-hour infusion, and stop the line immediately when a severe reaction develops.
Infliximab increases risk of serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and other opportunistic pathogens. Discontinue infliximab if a serious infection or sepsis develops. Test for latent TB before initiation; treat latent TB before starting therapy. Monitor all patients for active TB during treatment even when initial latent testing is negative. During every IV infusion, serious hypersensitivity—including anaphylaxis, hypotension, dyspnea, and urticaria—can occur during or within 2 hours; have emergency medications at the bedside and stop the infusion for severe reactions. The boxed warning also notes increased malignancy risk, including lymphoma and hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease. Doses >5 mg/kg are contraindicated in moderate or severe heart failure.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before starting every infliximab infusion, confirm no active infection, verify latent TB workup is complete, and ensure resuscitation drugs are available. During the ≥2-hour infusion, treat dyspnea, hypotension, chest pain, or urticaria as an infusion reaction—slow or stop the line and escalate per protocol; do not restart until the prescriber clears a severe event.
Most common brand names
Infliximab is the generic name for an intravenous TNF blocker available as the reference product and FDA-approved biosimilars. Verify the exact brand, vial strength (100 mg), calculated mg/kg dose, and infusion rate on the MAR—biosimilar names are easily confused with other biologics.
Common brands include Remicade (reference product) and biosimilars such as Inflectra, Renflexis, and Avsola. Infliximab is supplied as a single-entity 100 mg lyophilized vial for IV infusion—not combined in one bag with methotrexate or corticosteroids—but patients often receive those agents concurrently; duplicate biologic DMARD therapy (e.g., two TNF blockers) must be avoided.
Why we give it — Indications
Infliximab reduces inflammatory activity in autoimmune and autoinflammatory conditions. Nurses most often manage outpatient infusion-center visits: weight-based dose verification, continuous infusion monitoring for reactions, TB and infection screening, and coordination with pharmacy for reconstitution and dilution.
| Use | Detail |
|---|---|
| Inflammatory bowel disease | Reduces signs and symptoms, induces and maintains remission and mucosal healing, and supports corticosteroid withdrawal in adults with moderately to severely active Crohn’s disease or ulcerative colitis; pediatric CD and UC from age 6 years per Remicade labeling. |
| Rheumatology & dermatology | Approved for moderately to severely active rheumatoid arthritis (with methotrexate), active ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis when systemic therapy is appropriate. Monitor for fever and infection throughout therapy. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Infliximab is a chimeric IgG1 monoclonal antibody that binds tumor necrosis factor-alpha (TNF-α) and neutralizes its biological activity, reducing pro-inflammatory cytokine release and leukocyte migration into inflamed tissue. Elevated TNF is present in joints, gut mucosa, and psoriatic skin. By suppressing TNF-driven inflammation, infliximab improves symptoms—but also reduces immune defense against tuberculosis, fungi, and other pathogens. That is why nurses prioritize infection screening and continuous infusion monitoring for hypersensitivity before focusing on infusion pump setup alone.
Dosing overview
Dosing is weight-based and indication-specific; verify the prescriber order against current Remicade (infliximab) prescribing information and local protocol. Most IBD and psoriasis regimens use 5 mg/kg IV at weeks 0, 2, and 6 then every 8 weeks; RA uses 3 mg/kg with methotrexate per labeling.
Missed dose: Not specified in the reviewed prescribing information for a dedicated missed-infusion protocol. Contact the prescriber to reschedule maintenance infusions per the ordered interval; do not double doses unless specifically ordered.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information for symptom onset timing | Clinical improvement may take weeks after induction; do not assume lack of effect after the first infusion alone |
| Peak (IV) | Linear relationship between dose and maximum serum concentration for single IV doses 3–20 mg/kg | Infusion reactions can occur on first exposure—peak drug level does not predict reaction timing |
| Half-life | Median terminal half-life approximately 7.7–9.5 days after IV dosing across indications | Infection vigilance continues after held doses because drug persists; antibody development may increase clearance |
| Duration / steady state | Repeated infusions at 2 and 6 weeks produce predictable concentrations without systemic accumulation at maintenance intervals | Re-administration after a treatment gap increases infusion reaction risk per labeling—coordinate with prescriber before re-induction |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm no active infection—do not initiate infliximab during active infection; discontinue if infection becomes serious per boxed warning
- Verify latent tuberculosis testing (QuantiFERON-TB Gold or equivalent) is completed and treated when indicated before first dose; reassess TB risk periodically during therapy
- Review HBV status in at-risk patients, heart failure severity (doses >5 mg/kg contraindicated in moderate/severe HF), concomitant biologics, live-vaccine plans, and ensure emergency medications are available before IV start
Contraindications
- REMICADE doses >5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)
- Previous severe hypersensitivity reaction to infliximab or any inactive ingredient (including anaphylaxis, hypotension, serum sickness per labeling)
- Do not administer during active infection or when required pretreatment infection/TB workup is incomplete; avoid concurrent live vaccines and duplicate biologic DMARD therapy
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other TNF blockers / abatacept / anakinra | Concurrent TNF blockers or abatacept/anakinra with TNF blockers increased serious infections without added benefit in trials | Do not give concurrent doses; verify pharmacy/prescriber plan uses only one biologic; hold and clarify duplicate biologic orders (e.g., adalimumab plus infliximab) |
| Live vaccines / therapeutic infectious agents | Live vaccines and agents such as BCG bladder instillation can cause clinical or disseminated infections; fatal BCG infection reported in infant exposed in utero | Hold live-vaccine administration; wait at least 6 months after birth before live vaccines in infants exposed in utero per labeling |
| CYP450 substrates with narrow index (e.g., warfarin) | Infliximab may normalize cytokine suppression of CYP450 enzymes, changing drug levels when started or stopped | Monitor INR or drug levels when initiating or discontinuing infliximab with narrow-therapeutic-index agents per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous infusion after pharmacy reconstitution and dilution; administer over at least 2 hours with an in-line filter per Remicade labeling.
- Confirm weight-based dose calculation (mg/kg × current weight), brand/vial match, and that the prepared infusion begins within 3 hours of reconstitution and dilution
- Ensure personnel and medications to treat infusion reactions (acetaminophen, antihistamines, corticosteroids, epinephrine) are available before starting; premedication may include H1/H2 blockers, acetaminophen, and/or corticosteroids per prescriber order
- Monitor vital signs and patient symptoms throughout the infusion and for a period after completion; use dedicated IV access and verify no second biologic is scheduled
For mild to moderate reactions during infusion (e.g., flushing, chills, headache, rash), consider slowing or stopping the infusion per labeling. Upon resolution, may restart at a lower rate with premedication. Discontinue the infusion for severe hypersensitivity (anaphylaxis, hypotension, bronchospasm, angioedema). Also hold if the patient reports active infection symptoms such as cough with fever before the line is started.
Expected therapeutic response
- Reduced joint swelling, pain, and morning stiffness in arthritis indications over weeks to months after induction
- Decreasing CRP and improved functional scores when therapy is effective (lab trends vary by setting)
- GI symptom improvement in IBD and skin clearance in psoriasis—patients who do not respond by week 14 in CD are unlikely to respond with continued dosing per labeling; reassess with prescriber
Red flags — Stop and act
Infusion reactions and new infection symptoms on infliximab may escalate rapidly during the IV visit or in the days after. Escalate early rather than attributing dyspnea or hypotension to anxiety alone.
- Dyspnea, chest pain, hypotension, urticaria, or facial edema during or within 2 hours of infusion—stop infusion and treat per hypersensitivity protocol
- Delayed serum-sickness pattern (fever, rash, arthralgia, sore throat) within ~2 weeks after repeat infusion—hold next dose and notify prescriber
- Persistent fever, night sweats, or weight loss—consider TB reactivation or opportunistic infection
- Signs of sepsis (hypotension, tachycardia, dyspnea, rigors) or invasive fungal infection in endemic regions
- HBV flare (jaundice, elevated transaminases); new neurologic deficits; worsening heart failure symptoms at permitted doses
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Upper respiratory infection / sinusitis / pharyngitis | Common (>10% in labeling aggregate) | Differentiate mild viral symptoms from serious infection; hold next infusion and escalate if systemic or persistent |
| Infusion-related reactions (dyspnea, flushing, headache, rash) | Common; ~20% of infliximab patients vs 10% placebo in trials | Slow or stop infusion; treat per protocol; document reaction grade and prescriber plan for future premedication |
| Headache and abdominal pain | Common (>10%) | Monitor; evaluate for infusion reaction or infection if accompanied by fever or hypotension |
| Serious infections (TB, fungal, bacterial sepsis) | Boxed warning; may be fatal | Discontinue infliximab, urgent prescriber/ID evaluation, sepsis protocol when indicated |
| Malignancy / lymphoma | Boxed warning; increased versus controls in trials | Report new lymphadenopathy, B symptoms, or unexplained weight loss; prescriber surveillance |
| Hepatotoxicity, HF worsening, demyelinating disease, delayed hypersensitivity | Serious labeled warnings | Monitor LFTs when indicated; avoid >5 mg/kg in moderate/severe HF; stop and escalate per warning-specific pathway |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Single doses up to 20 mg/kg have been administered without any direct toxic effect per Remicade labeling.
Overdose management
- No specific antidote is listed in the reviewed prescribing information; management is supportive
- Monitor for signs or symptoms of adverse reactions or effects after supratherapeutic exposure
- Contact poison control or a medical toxicologist for additional guidance per labeling and facility protocol
Look-alike / sound-alike and error prevention
- Infliximab vs other biologics (adalimumab, etanercept, vedolizumab)—sound-alike names and biosimilar brands (Inflectra, Renflexis, Avsola) require independent double-check
- Remicade vs Rituxan (rituximab)—store and label IV biologic bags separately in pharmacy and infusion suite refrigerators
- Weight-based mg/kg errors—use two-nurse verification of patient weight, calculated dose, and number of vials before pharmacy release
- Duplicate biologic therapy—MAR may list infliximab plus another TNF blocker after formulary switch; hold and clarify
- Infusion rate errors—labeling requires ≥2-hour infusion; do not bolus or run on gravity without pump safeguards per protocol
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Not applicable—IV lyophilized powder reconstituted and diluted by pharmacy; do not administer undiluted bolus |
| Food timing | Not applicable to IV route |
| Storage | Refrigerate vials per product labeling; protect from light; reconstituted/diluted infusion must begin within 3 hours—do not store diluted bag for reuse |
| Infusion timing | Minimum 2-hour infusion with in-line filter; monitor first hour closely when prior reaction history exists |
| Missed infusion | Contact prescriber to reschedule per maintenance interval—do not double mg/kg dose unless ordered |
| Commonly missed | Skipping infection screen because it is a recurring maintenance visit; assuming prior negative TB test eliminates all TB risk; restarting at full rate after a mild prior reaction |
| Ask pharmacy when | Biosimilar substitution, re-induction after treatment gap, premedication changes after infusion reaction, or hold/resume after hospitalization for infection |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (≥65) and concomitant corticosteroids / methotrexate | Labeling notes greater serious infection incidence in geriatric infliximab patients—monitor with lower threshold for holding infusions |
| TB exposure, endemic mycoses regions, or chronic/recurrent infection history | Evaluate TB before and during therapy; consider empiric fungal evaluation if systemic illness occurs in histoplasmosis/coccidioidomycosis regions per labeling |
| HBV carriers and heart failure | Monitor HBV carriers for reactivation during and after therapy; doses >5 mg/kg contraindicated in moderate/severe HF—watch for worsening dyspnea or edema at permitted doses |
| Pregnancy | Observational data did not show increased major malformations versus non-biologics in reviewed studies, but findings were inconsistent and methodologically limited. Infliximab crosses the placenta in the third trimester; infants may be at increased infection risk and live vaccines should be deferred for at least 6 months after birth per labeling. Use during pregnancy only if clearly needed after risk/benefit discussion. |
| Lactation | Infliximab is present at low levels in human milk; systemic infant exposure expected low due to GI degradation. Published IBD cohort data showed no increased infant infection rates or developmental concerns, but data on milk production effects are limited per labeling—balance breastfeeding benefits against maternal disease control. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Infection symptoms at every infusion visit: temperature, cough, dysuria, wound appearance, travel history, TB exposure
- Vital signs before, during, and after infusion; TB screening per protocol when starting and periodically during therapy; LFTs when hepatotoxicity suspected
- Infusion reaction signs (flushing, dyspnea, urticaria, chest pain, hypotension), therapeutic response, and delayed hypersensitivity symptoms in the 2 weeks after infusion
Document
- Brand, calculated mg/kg dose, patient weight, lot if required, infusion start/stop times, rate changes, and reaction treatment given
- Pre-therapy TB/HBV review, premedications, hold actions, and prescriber notification for suspected infection or infusion reaction
- Patient teaching on infusion reaction symptoms, delayed reactions, live-vaccine avoidance, when to seek emergency care, and next infusion date
Patient teaching
- Report fever, persistent cough, night sweats, weight loss, burning urination, or spreading skin infection before any infusion—do not receive the next dose until cleared
- During infusion, tell staff immediately about chest tightness, difficulty breathing, throat swelling, hives, or dizziness—infusion may be slowed or stopped
- After infusion, report joint pain with fever and rash within 2 weeks (possible delayed reaction); avoid live vaccines during therapy and for 6 months after birth if exposed in utero per prescriber guidance
- Keep all scheduled maintenance infusion appointments; contact the clinic if you miss a visit rather than doubling doses at home
- Carry medical identification noting biologic immunosuppression if directed; inform dentists, surgeons, and emergency staff that you receive infliximab IV
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Active infection or new fever/infection symptoms until prescriber reassesses—do not start or continue during active infection
- Latent TB not yet treated when test is positive, or suspected TB reactivation (hold and escalate immediately)
- Moderate or severe heart failure with ordered dose >5 mg/kg; prior severe hypersensitivity to infliximab; scheduled live-vaccine administration
- Duplicate biologic/biosimilar order (adalimumab, etanercept, etc.), particulate/discolored solution, or wrong calculated mg/kg dose
- Severe infusion reaction during current visit—discontinue infusion and do not restart until prescriber clears
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Infusion centers and hospital biologic suites rely on nurses to gatekeep the IV line: infection assessment and reaction readiness are as critical as pump programming. Build TB screening and emergency drug availability into every visit, not only the first induction dose.
1. Check-before-you-give protocol
- Right patient, drug, brand, weight, mg/kg dose, diluent volume, and indication—confirm biosimilar substitution is intended
- Screen for infection: temperature, symptoms, recent antibiotics, hospitalizations, TB exposure, travel
- Verify emergency medications and trained staff are present; review concurrent immunosuppressants and confirm no second biologic is scheduled
- Inspect bag for particulates/discoloration, confirm infusion start within 3 hours of preparation, and program ≥2-hour rate with in-line filter
2. High-alert and safety badge
Not on standard high-alert medication lists, but carries a boxed warning for serious infection and malignancy with high-stakes IV infusion reaction riskTreat infliximab with biologic-level safety rigor: independent infection screen, weight-based dose verification, continuous infusion monitoring, and documented hold/escalation rules even at maintenance visits.
3. Clinical workflow: hold and question rules
- If dyspnea, hypotension, urticaria, or chest pain develops during infusion, stop or slow the line and activate the infusion-reaction protocol—document time and interventions
- If the patient reports fever ≥38 °C or infection symptoms before the visit, hold the infusion and notify the prescriber same day
- Serious infection or sepsis: discontinue infliximab per labeling and activate sepsis/infection protocol; do not resume until prescriber and ID team agree
4. Critical teach-back questions
- “What symptoms should you report during the infusion?” (Patient should name chest tightness, difficulty breathing, hives, throat swelling, dizziness, or feeling faint—and state they will alert the nurse immediately.)
- “What should you do if you develop fever and joint pain with rash in the week after an infusion?” (Patient should contact the prescriber/infusion clinic before the next dose—possible delayed hypersensitivity per labeling—and not assume it is a harmless viral illness alone.)
5. Care coordination
Prescriber / rheumatology or gastroenterology: Confirm indication-specific mg/kg regimen, re-induction after gaps, when to stop for lack of response, and plan for surgery or pregnancy
Pharmacist / infectious disease: Support reconstitution timing, biosimilar interchange, TB screening interpretation, premedication after prior reactions, and hold/resume decisions after serious infection
🧠 Quick mental checklist
- Any active infection or new fever/cough since the last infusion?
- Is latent TB documented and treated—or re-screening due?
- Are emergency drugs and staff ready; is the mg/kg dose double-checked?
- Is another biologic DMARD or live vaccine on the same plan?
- Infusion started within 3 hours of prep; ≥2-hour rate with filter programmed?
Infliximab NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for infliximab IV infusion safety using a tabbed infusion-center case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), delayed-reaction trend interpretation, documentation cloze, ordered escalation, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Infliximab 390 mg IV (5 mg/kg for 78 kg) every 8 weeks — infusion in progress (maintenance dose 14)
- Acetaminophen 650 mg PO, diphenhydramine 25 mg IV, methylprednisolone 40 mg IV — premedications given 30 min before start
- Methotrexate 15 mg PO weekly — last dose 5 days ago per patient report
- Pharmacy: Remicade bag verified; diluted infusion started 45 min after pharmacy prep
- CRP: 45 mg/L pre-induction → 18 mg/L at week 6 → 12 mg/L today (improving)
- QuantiFERON-TB Gold: negative (8 months ago, pre-start); no repeat ordered
- ALT/AST, CBC: within baseline range today
- No blood cultures ordered — patient denies fever before arrival
- Pre-infusion: temp 36.9 °C; BP 118/74; HR 78; RR 16; SpO2 98% room air
- Now: temp 37.6 °C; BP 92/58 mmHg; HR 112; RR 20; SpO2 95%
- Facial flushing and urticaria on chest observed; patient reports chest tightness
- Prior infusion (cycle 2): mild flushing — infusion slowed and completed with premedication
- 0830: 38-year-old with Crohn’s disease; denies cough, dysuria, or recent antibiotics
- 0915: Infusion started at ordered rate over 2 hours with in-line filter
- 0955: Nurse noted flushing and urticaria; patient anxious but alert and oriented
- Epinephrine, antihistamines, and oxygen available at bedside per protocol
Answer key & rationale
Frequently asked questions
What should a nurse do first if a patient develops dyspnea and hypotension during infliximab infusion?
Stop or slow the infusion per protocol, assess airway and vital signs, and treat per facility hypersensitivity pathway. Remicade labeling directs discontinuing the infusion for severe hypersensitivity and having acetaminophen, antihistamines, corticosteroids, and epinephrine available before each infusion.
When should infliximab be held before an infusion?
Hold when there is active or suspected serious infection, positive untreated latent TB, moderate or severe heart failure with doses above 5 mg/kg, prior severe hypersensitivity to infliximab, particulate or discolored product, duplicate biologic therapy, or scheduled live vaccines. Labeling directs discontinuing infliximab if a serious infection or sepsis develops.
What adverse effects are most common with infliximab?
Labeling reports infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, and abdominal pain in more than 10% of patients. Serious infections, malignancies, hepatotoxicity, heart failure worsening, delayed hypersensitivity, and anaphylaxis during infusion are labeled warnings requiring escalation.
How long must infliximab IV infusion run?
Remicade labeling requires intravenous infusion over at least 2 hours with an in-line filter. The prepared infusion should begin within 3 hours of reconstitution and dilution; do not store the diluted solution for reuse.
Is there an antidote for infliximab overdose?
No specific antidote is listed. Single doses up to 20 mg/kg have been administered without direct toxic effect per labeling. Management is supportive monitoring for adverse reactions; contact poison control or medical toxicology services per facility protocol and local guidance.
Can infliximab be given during an active respiratory infection?
Do not initiate infliximab during active infection and discontinue if infection becomes serious per the boxed warning. Hold the scheduled infusion, treat the infection, and obtain prescriber clearance before resuming therapy.
References
-
U.S. National Library of Medicine. REMICADE (infliximab) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
-
U.S. Food and Drug Administration. Remicade (infliximab) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf
-
U.S. Food and Drug Administration. Drug Safety Communication — Updated information on unapproved uses of TNF blockers.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-unapproved-uses-anti-tnf-blockers
-
Centers for Disease Control and Prevention. Tuberculosis (TB) — Clinical testing and diagnosis.https://www.cdc.gov/tb/hcp/testing-diagnosis/index.html
-
Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings.https://www.ismp.org/recommendations/high-alert-medications-acute-list
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.